SEOM Clinical Guideline for gastrointestinal sarcomas (GIST) (2016)

• A. Poveda ^[1] ; V. Martinez ^[2] ; C. Serrano ^[6] ; I. Sevilla ^[7] ; M. J. Lecumberri ^[3] ; R. D. de Beveridge ^[8] ; A. Estival ^[9] ; D. Vicente ^[4] ; J. Rubió ^[9] ; J. Martin-Broto ^[5]
  1. [1] Instituto Valenciano de Oncologia

     Instituto Valenciano de Oncologia

     Valencia, España

     
  2. [2] Hospital Universitario La Paz

     Hospital Universitario La Paz

     Madrid, España

     
  3. [3] Gobierno de Navarra

     Gobierno de Navarra

     Pamplona, España

     
  4. [4] Hospital Universitario Virgen Macarena

     Hospital Universitario Virgen Macarena

     Sevilla, España

     
  5. [5] Hospital Universitario Virgen del Rocío

     Hospital Universitario Virgen del Rocío

     Sevilla, España

     
  6. [6] Instituto de Oncología Vall d’Hebron, España
  7. [7] Instituto de Investigaciones Biomédicas de Málaga, España
  8. [8] Hospital Universitario y Politécnico La Fe, España
  9. [9] Instituto Catalán de Oncología, España

  Mostrar afiliaciones +
• Localización: Clinical & translational oncology, ISSN 1699-048X, Vol. 18, Nº. 12 (December 2016), 2016, págs. 1221-1228
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal neoplasms of the digestive tract, and this disease has served as a paradigmatic model for successful rational development of targeted therapies. The introduction of tyrosine kinase inhibitors with activity against KIT/PDGFRA in both localized and advanced stages has remarkably improved the survival in a disease formerly deemed resistant to all systemic therapies. The Spanish Society of Medical Oncology (SEOM) guidelines provide a multidisciplinary and updated consensus for the diagnosis and treatment of GIST patients. We strongly encourage that the managing of these patients should be performed within multidisciplinary teams in reference centers.